FGFR3, a tyrosine kinase receptor gene, is located at chromosome 4p16. 3 and is composed of 19 exons [14]. The extracellular portion can bind with fibroblast growth factors, initiating cascades of downstream signals that ultimately influence cell growth, migration, angiogenesis, and differentiation [14].

Researchers believe that the FGFR3 protein regulates bone growth by limiting the formation of bone from cartilage (a process called ossification), particularly in the long bones.

Genetics. Achondroplasia is a single gene disorder? caused by mutations? in the FGFR3 gene? on chromosome? 4. Two different mutations in the FGFR3 gene cause more than 99 per cent of cases of achondroplasia.

Achondroplasia comes from the genetic point mutations in the fibroblastic growth factor receptor 3 gene (FGFR3), which enables abnormal cartilage growth-plate differentiation and insufficient bony development.

Only a single copy of the mutated FGFR3 gene results in achondroplasia. It is generally caused by spontaneous mutations in germ cells; roughly 80 percent of the time, parents with children that have this disorder are normal size.

Native ligands for FGFR3; FGF1, FGF2, and FGF9 compete for binding to FGFR3 and block BoNT/A cellular uptake. These findings show that FGFR3 plays a pivotal role in the specific uptake of BoNT/A across the cell membrane being part of a larger receptor complex involving ganglioside- and protein-protein interactions.

This genetic disorder is caused by a change (mutation) in the fibroblast growth factor receptor 3 (FGFR3) gene. Achondroplasia occurs as a result of a spontaneous genetic mutation in approximately 80 percent of patients; in the remaining 20 percent it is inherited from a parent.

Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. Dwarfism is defined as a condition of short stature as an adult. People with achondroplasia are short in stature with a normal sized torso and short limbs. It’s the most common type of disproportionate dwarfism.

FGFR3, a tyrosine kinase receptor gene, is located at chromosome 4p16.3 and is composed of 19 exons [14]. The extracellular portion can bind with fibroblast growth factors, initiating cascades of downstream signals that ultimately influence cell growth, migration, angiogenesis, and differentiation [14].

Fibroblast growth factor receptor 3 is a protein that in humans is encoded by the FGFR3 gene. FGFR3 has also been designated as CD333 (cluster of differentiation 333). The gene, which is located on chromosome 4, location p16.3, is expressed in tissues such as the cartilage, brain, intestine, and kidneys.

Activating mutations of FGFR3 are well known to cause a variety of short limbed bone dysplasias and craniosynostosis syndromes including achondroplasia, hypochondroplasia, thanatophoric dysplasia I and II, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAM) syndrome, and lacrimo-auriculo-dental-digital (LADD) syndrome.

Perez-Castro et al. (1997) reported that the human and mouse FGFR3 amino acid sequences share 92% homology. Scotet and Houssaint (1995) identified splice variants of FGFR3 that use 2 alternative exons, 3b and 3c, encoding the C-terminal half of Ig domain 3.